Mr. Speaker, in terms of the comprehensiveness of the bill, it certainly addresses a lot of the right areas, and a lot will remain to be done by regulation.
We want to see the transparency that I referred to around all trials. All drug trials should be registered and their results made public. We want to see transparency around Health Canada's decisions on whether it is going to allow a drug or not, around the area of fines, and around drug recalls. We need to have much better information on the side effects of prescription drugs. As well, the labelling should be as clear as possible so that anyone with a prescription drug is able to see, without having to search out secondary materials, whether there are significant side effect risks with this drug.
Those pieces are coming in subsequent regulations, but when we go to committee, we will study it more closely. We are in somewhat of a hurry, because the sooner we act, the more Canadians can be protected from drugs that they never would have used if they had known of their health risks.